US Patent

US8895586 — Methods of treating emesis

Method of Use · Assigned to Individual · Expires 2032-05-23 · 6y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent discloses methods for preventing and/or treating diseases mediated by the neurokinin (NK1) receptor.

USPTO Abstract

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor. The compounds have the general formula (I):

Drugs covered by this patent

fosnetupitant-chloride-hydrochloride (FOSNETUPITANT CHLORIDE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2301`	—	fosnetupitant-chloride-hydrochloride
`U-2301`	—	fosnetupitant-chloride-hydrochloride

Patent Metadata

Patent number: US8895586
Jurisdiction: US
Classification: Method of Use
Expires: 2032-05-23
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.